You are here
NDA Submitted for Somatostatin Analog Sanvar, Treatment for Esophageal Variceal Bleeding
"I am very pleased that H3 Pharma has become one of the few companies in Quebec to submit an NDA and has been able to do so within the tight timeframe we had planned," said Dr. Loic Maurel, President and CEO of the Company. "The submission of this NDA moves us significantly closer to commercialization of this product candidate. We are now in active discussions with a number of pharmaceutical companies to conclude commercialization agreements in the key world markets of the Americas and Europe this year. The orphan-drug status we have received in the U.S.A. will give us exclusivity in that market for seven years following approval and we expect to enter the U.S. market in 2005," he added.
"I want to thank our dedicated staff for their enormous efforts to move this product candidate forward quickly and I want to acknowledge the excellent work of the team at Debiopharm S.A. in Lausanne, Switzerland, who advanced the development work so effectively up until our in-licensing of the product last July," said Dr Maurel.
Sanvar(R) IR is the only somatostatin analog to demonstrate success versus placebo in the treatment of acute EVB, in a well powered and designed Phase III clinical study conducted in 227 patients in 22 centers. Sanvar(R) IR significantly reduced active bleeding. Survival with hemostasis at 5 days was achieved significantly (p equal 0.021) more often with Sanvar(R) IR than with placebo. In patients with control of bleeding at day 5, Sanvar(R) IR significantly (p equal 0.006) increased hemostasis and survival through day 42. Sanvar(R) IR will therefore be used valuably in association with endoscopic treatment to improve hemostasis in emergency in cirrhotic patients presenting variceal bleeding.
The Sanvar(R) IR formulation was submitted for registration in Mexico in December 2003. European submission is planned for late 2004.
Sustained-Release Formulation Also Under Development in Other Indications
The Company is also developing a three-month sustained release (SR) formulation of Sanvar(R) for the management of life-long symptoms of carcinoid tumors and acromegaly for which it was granted orphan-drug designation by the FDA in November 2003. The sustained release formulation offers significant therapeutic advantages over other somatostatin analogues in the treatment of these diseases. Sanvar(R) has demonstrated positive effects on the clinical symptoms of Crohn's disease as well, and further clinical development will begin this spring.
H3 Pharma plans to sign out-licensing agreements for all Sanvar(R) indications and formulations this year.
Source: H3 Pharma Inc.